SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology ...